Meet AskFRE!
AskFRE is the AI powered Investor Relations assistant from Fresenius, designed to make capital markets information easier and faster to access.
Integrated directly into each Investor Relations subpage, AskFRE allows you to ask questions in natural language and receive direct answers on financial results, company updates and other Investor Relations topics – available 24/7.
All responses are based exclusively on publicly available Fresenius disclosures.
By providing a faster and more intuitive way to navigate financial information, AskFRE supports transparent, timely and user focused communication – and enhances the overall digital Investor Relations experience at Fresenius.
You can access AskFRE on each Investors subpage by clicking the chatbot icon in the lower right corner of your screen.
What you need to know
- Languages: Available in English and German (use the standard language switch in the top right corner of the website)
- Coverage: Information from the last five years up to today
- Sources: Each answer includes the exact source reference (e.g. document and page number)
- Data basis: Only publicly available content from the Fresenius Investor Relations website (HTML pages and PDF documents)
- Data protection: Please access all information here.
Important notice: AI generated responses may be incomplete or contain inaccuracies. For more information, please refer to the Terms of Use.
Feedback: Suggestions for improvement, missing content or functional issues – please contact us at ir-fre@fresenius.com.
How to use AskFRE
To get the most accurate results, we recommend:
- Ask precise questions, including a specific topic and, if relevant, a time frame
- Use the source links provided to directly access the underlying documents (e.g. Annual Reports or presentations)
- Refine your question if the answer is too broad or not specific enough
Try some of these example questions to interact with AskFRE:
- What is #FutureFresenius about?
- What are the main business updates from the Fresenius Q1 2026 results?
- How many hospitals does Fresenius Helios operate in Germany?
Contact
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
Download
International financial analysts cover Fresenius SE & Co. KGaA and publish reports and updates on the development of its business and its shares. Once a quarter, VARA Research creates an up-to-date consensus from these various forecasts. An interactive and downloadable set of the consensus data for Fresenius SE & Co. KGaA can be found on Vara Research.
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Download
Related Links
Interactive Tool
August 05, 2026
Bad Homburg, Germany
Conference Call Q2 2026
Financial Results
Q2/2026: Excellent Q2 performance demonstrates structural step-up
Outlook
FY/26 guidance raised: Fresenius outlook at a glance.
Financial Reports
Discover Fresenius financial reports and presentations here!
Goals & Strategy
#FutureFresenius is clearly paying off. Find out more about our company’s strategy!
"Fresenius delivered another excellent quarter and, from a position of operational strength, is raising its full-year guidance. (...) This reflects not only strong execution but also a structural step-up in earnings quality. Fresenius today has a fundamentally different earnings, returns, and cash-generation profile than it did in 2022. (...) #FutureFresenius is delivering exactly what it was designed to achieve: a stronger, higher-quality, more innovation-led and faster-growing Fresenius that can deliver better outcomes for patients and create long-term value for shareholders."
Michael Sen, Chairman of the Management Board
Financial Highlights Q2/2026
Group Revenue 1
€ 5864 m
+6% 2
Q2/25: €5,571 m
Group EBIT 1
€ 719 m
+10% 4
Q2/25: €654 m
Core Net income 1, 3
€ 470 m
+14% 4
Q2/25: €412 m
Core EPS 1, 3
€ 0.83
+14% 4
Q2/25: €0.73
KABI Revenue 1
€ 2244 m
+7% 2
Q2/25: €2,111 m
HELIOS Revenue 1
€ 3526 m
+5% 2
Q2/25: €3,370 m
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Excluding Fresenius Medical Care and Vitrea
4 Constant currency growth
Letter to our shareholders
Over the past three years, we have successfully implemented our #FutureFresenius strategy and created a new Fresenius that is innovative, relevant, resilient, and adaptable. Read the full CEO-letter!
Sustainability Statement
Our Sustainability Statement shows how we address environmental, social, and governance topics and manage the associated impacts, risks, and opportunities. Read more here!
Strategy and goals
Our vision is to be the trusted, market-leading healthcare company that unites cutting-edge technology and human care to shape next-level therapies. Read more about our corporate strategy!
Rejuvenate
In 2025, Fresenius entered the next phase of our #FutureFresenius strategy: Rejuvenate. We have defined three priorities that guide our actions across the entire company. Discover more in the stories.
Investor Feedback
Open dialogue is valuable for us.
You can submit your feedback quickly and easily using the link below (anonymously if you prefer).
You will be redirected to QuantiFire which conducts this survey in own controllership.
News
-
Fresenius expands European production capacity to enhance healthcare supply chain resilience
![]()
Fresenius expands European production capacity to enhance healthcare supply chain resilience
Fresenius is strengthening its European manufacturing network with new and expanded production capabilities for intravenous (IV) fluids in Poland and Italy. This week, the company opened a new IV fluids production line in Kutno, Poland, and expanded its manufacturing and warehouse infrastructure in Isola della Scala, Italy.
September 25, 2026 · Fresenius Kabi
-
Fresenius expands Medical Nutrition Portfolio with new real-food-based enteral nutrition concept
![]()
Fresenius expands Medical Nutrition Portfolio with new real-food-based enteral nutrition concept
NutriChef launches in several European markets and combines real food ingredients1 with the consistency and nutritional completeness of medical nutritionThe launch of NutriChef, the fifth product launch within Fresenius’ Medical Nutrition portfolio in 2026, reflects the company’s commitment to patient-centered innovation-led growth and further strengthens its portfolio in nutritional careNutriChef expands Fresenius’ enteral nutrition offering with a real-food-based concept designed around the needs of patients, caregivers, and healthcare professionalsMedical Nutrition is an attractive healthcare market supported by aging populations, increased demand for homecare, and growing awareness of the role of nutrition in patient careFresenius announced today the launch of NutriChef, a new enteral nutrition option that combines real food ingredients1 such as fruit and vegetables while maintaining the nutritional completeness required for medical nutrition, in Germany, Switzerland, Norway, Netherlands, Denmark, and Sweden.The product is designed to bridge the gap between conventional formula-based tube feeding and the familiarity associated with real meals and home-prepared foods. Available in three nutritionally complete, meal-inspired varieties2, they contain ingredients derived from 21 different plants and more than 75 percent real food ingredients, including water and oils1. The product provides high energy and protein as well as a blend of soluble and insoluble fibers.“For many patients, the challenge is not only getting the nutrition they need. It is adapting to a new reality,” said Sebastien Guery, Executive Vice President Business Unit Medical Nutrition. “NutriChef responds to that need by combining familiar foods into enteral feeding with the safety, consistency and nutritional standards required in medical care. It is also a testament to the innovation-led growth of Fresenius, reflecting our ability to translate evolving patient needs into differentiated innovations and meaningful portfolio expansion.”Developed for patients who require enteral nutrition, the new offering combines familiar food-based ingredients with the reliability and quality standards expected from medical nutrition. It offers patients, caregivers, and healthcare professionals an additional option that brings familiar food concepts into nutritional care.As populations age and more care shifts beyond the hospital into outpatient and homecare settings, nutritional support is becoming increasingly important across healthcare systems. Fresenius continues to see strong long-term demand in Medical Nutrition, supported by demographic trends, growing awareness of disease-related malnutrition, and the need for solutions that fit into patients’ daily lives.As the fifth addition to Fresenius’ Medical Nutrition portfolio introduced in 2026, NutriChef underscores the company’s continued investment in nutritional care across enteral and parenteral nutrition, the company continues to expand access to high-quality medical nutrition while addressing practical challenges faced by patients, caregivers, and healthcare professionals. As part of #FutureFresenius, the company continues to strengthen its portfolio with differentiated solutions that address evolving patient needs.NutriChef is a food for special medical purposes for the dietary management of disease-related malnutrition, to be used under medical supervision. Product availability may vary by market.NutriChef is essentially designed as an adult medical nutrition product, with limited, controlled use in:children >3 years (restricted)adolescents (possible full use only with medical supervision)References1 Fresenius Kabi. NutriChef Ingredient List and Product Specification. Fresenius Kabi; 2026.2 Fresenius Kabi Market Research; Real Food & Tube Feeding Insights Study, 2022.
September 07, 2026 · Fresenius Kabi
-
Brief News
Q2 2026 Aide Memoire available
Fresenius announced today that the Company's Q2 2026 Aide Memoire is now available on the Company's financial results section.As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q2 2026 financial results will be published on August 5, 2026.
July 15, 2026 · Fresenius
-
Brief News
GKV Stabilization Act approved
The German Bundestag and Bundesrat approved the Act to Stabilize Contributions Rates in the Statutory Health Insurance System (GKV-Beitragssatzstabilisierungsgesetz) on July 10, 2026.
July 13, 2026 · Fresenius
-
Brief News
AI assistant enhances access to Investor Relations information
Today, Fresenius has launched the AI-powered assistant – “AskFRE” – on its Investor Relations (IR) website, marking an important step in advancing its digital capital markets communications. The solution is a joint initiative of the Fresenius AI Center of Excellence and the Investor Relations team.With AskFRE, visitors can now interact with an integrated AI chatbot that provides direct answers to capital market-relevant information. This includes financial results, company updates and other IR content – based exclusively on publicly available Fresenius disclosures.In an increasingly fast-paced and data-driven environment, digital investor relations play a key role in delivering timely, transparent and stakeholder-focused communication. AskFRE supports this ambition by enabling more intuitive access to financial information and tailored user interactions, while reinforcing the consistency and accessibility of Fresenius’ disclosures.With AskFRE, Fresenius underscores its commitment to advancing a best in class digital investor relations experience.AskFRE is now available: https://www.fresenius.com/AskFRE-Your-IR-Assistant
May 26, 2026 · Fresenius
Stay Connected with Fresenius Investor Relations on LinkedIn
Follow Fresenius Investor Relations for expert insights and latest news that contribute to the Fresenius equity story, and exclusive content from our team. Join our growing community and be part of the conversation!
Fresenius announced today that the Company's Q2 2026 Aide Memoire is now available on the Company's financial results section.
As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q2 2026 financial results will be published on August 5, 2026.
The German Bundestag and Bundesrat approved the Act to Stabilize Contributions Rates in the Statutory Health Insurance System (GKV-Beitragssatzstabilisierungsgesetz) on July 10, 2026. This completes the parliamentary process.
Fresenius’ perspective in brief:
- Fresenius’ Full Year 2026 guidance is unchanged.
- The approved Act preserves annual hospital reimbursement growth, and on balance, is more favourable than the Cabinet Draft, confirming the direction the Company flagged in April 2026.
- Fresenius Helios’ revenue growth and 10-12% EBIT margin ambition as part of the Fresenius Financial Framework remains unchanged.
Please find the full Market Briefing here: Analyst & Consensus.
Bonds 2026 – 2034
Issuer | Fresenius SE & Co. KGaA |
Currency | € |
Issue amount | 500,000,000 |
Value date | July 08, 2026 |
Maturity | July 08, 2034 |
Coupon | 3.750% |
Coupon payment | July 08 |
Rating | BBB / Baa3 / BBB- |
Stock exchange | Luxembourg / Regulated Market |
Denomination | 1,000 |
Clearing agency | Clearstream Luxembourg / Euroclear |
ISIN Code | XS3435670222 |
Bonds 2026 – 2031
Issuer | Fresenius SE & Co. KGaA |
Currency | € |
Issue amount | 500,000,000 |
Value date | July 08, 2026 |
Maturity | July 08, 2031 |
Coupon | 3.375% |
Coupon payment | July 08 |
Rating | BBB / Baa3 / BBB- |
Stock exchange | Luxembourg / Regulated Market |
Denomination | 1.000 |
Clearing agency | Clearstream Luxembourg / Euroclear |
ISIN Code | XS3435668325 |
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SINGAPORE OR JAPAN.
---
Fresenius SE & Co. KGaA announced the successful issuance of a €1 billion dual-tranche bond offering on July 1, 2026. The bonds are expected to settle on July 8, 2026.
The transaction consists of the following two tranches:
- €500 million of fixed rate notes with a coupon rate of 3.375%, maturing July 8, 2031; and
- €500 million of fixed rate notes with a coupon rate of 3.750%, maturing July 8, 2034.
Fresenius will use the net proceeds of the offering for general corporate purposes, including the refinancing of existing financial liabilities.
The bonds were issued by Fresenius SE & Co. KGaA under the Fresenius Debt Issuance Program. The company has applied to have the bonds admitted to trading on the regulated market of the Luxembourg Stock Exchange.
The bond issuance does not impact Fresenius' full-year 2026 financial guidance, and the transaction fully covers refinancing requirements for the full year 2026 while proactively addressing certain debt maturities in 2027.
Overall, the transaction further strengthens Fresenius’ financial flexibility, limits potential future refinancing risks, and supports the balance sheet. In addition, the Company successfully extends the average maturity of its debt portfolio. Fresenius remains committed to its self-imposed target leverage corridor of 2.5 to 3.0x net debt/EBITDA. Deleveraging and a strong balance sheet are clear priorities within the Company’s stated capital allocation priorities, which are key to delivering the ambitions of #FutureFresenius.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, Singapore or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or Singapore or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or Singapore. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada, Japan or Singapore. There will be no public offer of the securities in the United States.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
This announcement is a general information and not a prospectus. It has been prepared on the basis that any offer of securities in any Member State of the European Economic Area ("EEA") will be made pursuant to the prospectus and any supplement thereto prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) from the requirement to publish a prospectus for offers of securities. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus, as supplemented, in combination with the relevant final terms relating to such securities, to be issued by the company in connection with the offering of such securities. The applicable final terms for such securities, when published, will be available on the website of the Luxembourg Stock Exchange (www.LuxSE.com) together with the prospectus and any supplement thereto. Copies of the prospectus are also available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.